Home・Listă Acțiuni・CRISPR Therapeutics AG

CRISPR Therapeutics AG

Închisă

SectorSănătate

58.33 3.53

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

56.34

Maxim

59.15

Indicatori cheie
By Trading Economics
Venit	-91M -214M
Vânzări	8.7M 10M
EPS	-0.94
Marjă de profit	-2,102.79
Angajați	393
EBITDA	7.3M -110M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+30.1% upside

Dividende
By Acuity
Următoarele câștiguri	9 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	519M 5.1B
Deschiderea anterioară	54.8
Închiderea anterioară	58.33

Sentimentul știrilor

By Acuity

26%

74%

43 / 339 Clasament în Healthcare

CRISPR Therapeutics AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 sept. 2026, 23:51 UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

19 sept. 2026, 00:02 UTC

Correlated Moves

CRISPR Therapeutics AG is advancing in after-market trading, likely in sympathy with Editas Medicine Inc, amid broader economic concerns.

18 sept. 2026, 23:01 UTC

CRISPR Therapeutics AG is advancing in after-market trading, moving higher alongside the broader market, following a peak return earlier in the session.

17 sept. 2026, 23:51 UTC

CRISPR Therapeutics AG declined modestly during after-market hours on Thursday, breaking a recent trend of higher daily closes.

16 sept. 2026, 23:16 UTC

CRISPR Therapeutics AG is declining in after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

15 sept. 2026, 23:01 UTC

CRISPR Therapeutics AG shares are higher in after-market hours, reflecting overall market momentum despite a decline in the New York Empire State Manufacturing Index.

14 sept. 2026, 23:01 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting a strong performance despite declining major indices and rising crude oil prices.

11 sept. 2026, 23:01 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, influenced by a narrower-than-expected U.S. budget deficit of $167 billion for August.

10 sept. 2026, 20:07 UTC

CRISPR Therapeutics AG shares are lower amid a broader market decline following the European Central Bank's interest rate hike and rising Treasury yields.

8 sept. 2026, 20:07 UTC

CRISPR Therapeutics AG shares are lower today, marking four consecutive sessions of declines amid market speculation on potential interest rate hikes.

4 sept. 2026, 23:37 UTC

Correlated Moves

CRISPR Therapeutics AG shares rose in after-market trading, reflecting a modest increase since Friday's close, aligning with Beam Therapeutics' sector performance.

3 sept. 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-hours trading, continuing a decline since Thursday's close, despite broader market gains. No specific news was identified.

2 sept. 2026, 19:46 UTC

CRISPR Therapeutics AG shares are lower today, continuing a four-day decline amid rising U.S. Treasury yields and inflationary pressures affecting the biotechnology sector.

1 sept. 2026, 23:06 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, with no specific news identified to explain the movement. The stock has declined in three consecutive sessions.

31 aug. 2026, 23:06 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting stable performance amid broader economic sentiment and expectations for a potential rate hike.

29 aug. 2026, 00:02 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, continuing a trend of notable weakness amid rising market expectations for an interest rate hike.

28 aug. 2026, 22:51 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, continuing a trend of weakness since Friday's close with no specific news identified.

27 aug. 2026, 23:02 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting overall strength despite a slight pullback from earlier highs. No specific news was identified.

26 aug. 2026, 23:02 UTC

CRISPR Therapeutics AG shares are higher in after-market hours, maintaining strength above the 20-day moving average and near the upper end of their one-month range.

25 aug. 2026, 23:06 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, reflecting a decline after Tuesday's close, despite a significant gain over the past month.

24 aug. 2026, 23:01 UTC

Shares of CRISPR Therapeutics AG declined in after-market trading, despite briefly recovering earlier in the session. The stock remains above its 20-day moving average.

21 aug. 2026, 23:36 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the one-month range's upper end.

20 aug. 2026, 19:51 UTC

Correlated Moves

Shares lower today amid broader market pressures; SPDR S&P Biotech declines.

19 aug. 2026, 23:01 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, continuing a decline since Wednesday's close amid notable volatility.

18 aug. 2026, 22:16 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting unusual downward momentum amid broader market declines in major U.S. tech stocks.

17 aug. 2026, 23:06 UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market sentiment affecting small-cap stocks amid a slight decline in the Russell 2000 Index.

14 aug. 2026, 19:16 UTC

CRISPR Therapeutics AG shares are lower today amid broader investor caution following a decline in U.S. retail sales for July.

13 aug. 2026, 23:46 UTC

Correlated Moves

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid favorable economic conditions.

11 aug. 2026, 19:21 UTC

CRISPR Therapeutics AG shares are trading higher amid rising oil prices and inflation concerns ahead of upcoming U.S. inflation data. No specific news was identified.

10 aug. 2026, 23:06 UTC

No specific news was identified for CRISPR Therapeutics AG, which traded roughly flat during after-market hours, remaining near the upper end of its one-month range.

Comparație

Modificare preț

CRISPR Therapeutics AG Așteptări

Obiectiv de preț

By TipRanks

30.1% sus

Prognoză pe 12 luni

Medie 73.583 USD 30.1%

Maxim 110 USD

Minim 45 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCRISPR Therapeutics AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

13 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 13 analiști care au acordat evaluări ale acțiunilor CRISPR Therapeutics AG - Dist în ultimele 3 luni.

Sentiment

By Acuity

43 / 339 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.